Press ReleasesLatest news from MBio
MBio to Present at the Bio Investor Forum
October 1, 2020 Boulder, CO – MBio Diagnostics CEO, Chris Myatt, will deliver a Company presentation, including fund raising, progress on the LightDeck COVID-19 Total Antibody Test and other product pipeline updates at the upcoming Bio Investor Forum virtual event October 13-15. Please contact us to set up a one-on-one session with Chris and our executive team.
About MBio Diagnostics
MBio believes in a new approach to healthcare, where rapid and accurate diagnostic tests will be run wherever and whenever they are needed, without compromise. MBio’s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and manufacturing techniques to deliver lab-quality results anywhere in just a few minutes. MBio is launching our first on-the-spot in vitro diagnostic tests to help fight the COVID-19 pandemic, while also developing a portfolio of highly accurate, host-response panels to manage acute infections and sepsis, and next generation tests for heart attack triage. The LightDeck platform is already shipping and achieving success in veterinary diagnostics and for environmental testing. Learn more at www.MBioDx.com
Chief Marketing Officer
267-496-6391 ● Carrie.Mulherin@MBioDx.com